Rappa G, Lorico A, Sartorelli A C
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.
Cancer Res. 1990 Oct 15;50(20):6723-30.
Topoisomerase II has been suggested to have a role in the early events of differentiation. This possibility was evaluated by measuring the effects of inhibitors of topoisomerase II on the induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells. Differentiation of this cell line was induced along the granulocytic pathway by treatment with the topoisomerase II inhibitors novobiocin (150-300 microM), teniposide (20-50 nM), etoposide (0.1 microM), elsamicin (0.5 microM), and doxorubicin (40 nM). Maturation was assessed by the morphological appearance of mature forms of the granulocytic lineage, an increase in cell surface Fc receptors, the ability to reduce nitroblue tetrazolium, and the loss of proliferative capacity. In contrast, the non-topoisomerase II-reactive agent cisplatin and the topoisomerase I-reactive drug camptothecin did not cause the maturation of WEHI-3B D+ cells. Aclacinomycin A and retinoic acid, which are known efficacious inducers of the differentiation of this cell line, affected topoisomerase II extracted from WEHI-3B D+ cells in vitro, causing concentration-dependent inhibition of the strand-passing activity of the enzyme. Treatment of WEHI-3B D+ cells with novobiocin at 150 microM for 3 h or with teniposide at 50 nM for 24 h resulted in a 2- to 3-fold increase in etoposide-induced protein-DNA cross-links. Nuclear proteins in 0.35 M NaCl extracts from cells treated with novobiocin at 150 microM for 3 h or with teniposide at 50 nM for 24 h showed a slight increase in topoisomerase II activity compared to untreated cells. No changes in topoisomerase II levels, as measured by immunoblotting, were detected after treatment of WEHI-3B D+ cells with 150 microM novobiocin or 50 nM teniposide during the first 2 days of treatment. At day 3 of treatment, however, a decrease in topoisomerase II was observed in cells treated with either drug, possibly due to decreased cellular proliferation consequent to cell differentiation. The findings support the conclusion that topoisomerase II may have a role in the induction of granulocytic differentiation of WEHI-3B D+ leukemia cells.
有人提出拓扑异构酶II在分化的早期事件中起作用。通过测量拓扑异构酶II抑制剂对WEHI-3B D+单核细胞白血病细胞分化诱导的影响来评估这种可能性。用拓扑异构酶II抑制剂新生霉素(150 - 300 microM)、替尼泊苷(20 - 50 nM)、依托泊苷(0.1 microM)、埃尔斯米星(0.5 microM)和阿霉素(40 nM)处理,可诱导该细胞系沿粒细胞途径分化。通过粒细胞系成熟形式的形态外观、细胞表面Fc受体的增加、还原硝基蓝四氮唑的能力以及增殖能力的丧失来评估成熟情况。相比之下,非拓扑异构酶II反应性药物顺铂和拓扑异构酶I反应性药物喜树碱不会导致WEHI-3B D+细胞成熟。阿克拉霉素A和视黄酸是已知的该细胞系分化有效诱导剂,它们在体外影响从WEHI-3B D+细胞中提取的拓扑异构酶II,导致该酶的链通过活性受到浓度依赖性抑制。用150 microM新生霉素处理WEHI-3B D+细胞3小时或用50 nM替尼泊苷处理24小时,会使依托泊苷诱导的蛋白质 - DNA交联增加2至3倍。与未处理细胞相比,用150 microM新生霉素处理3小时或用50 nM替尼泊苷处理24小时的细胞,其0.35 M NaCl提取物中的核蛋白显示拓扑异构酶II活性略有增加。在用150 microM新生霉素或50 nM替尼泊苷处理WEHI-3B D+细胞的前两天,通过免疫印迹测量未检测到拓扑异构酶II水平的变化。然而,在处理的第3天,用这两种药物处理的细胞中观察到拓扑异构酶II减少,这可能是由于细胞分化导致细胞增殖减少所致。这些发现支持拓扑异构酶II可能在WEHI-3B D+白血病细胞的粒细胞分化诱导中起作用这一结论。